National Institute for Health Research (NIHR) Clinical Research Network
Exhibiting at booth 5b
Working in partnership with the life sciences industry
- Access to NHS clinical expertise
- Accurate national and local feasibility
- Streamlined site identification
- Study set-up support
- Proactive performance monitoring
- All free of charge
Funded by the UK government, the National Institute for Health Research (NIHR) Clinical Research Network (CRN) delivers high quality research in partnership with the UK’s National Health Service (NHS). Our Study Support Service is free of charge and helps the life sciences industry plan, set-up and deliver high quality research to time and target, across all therapeutic areas.
We are your route to accessing the UK’s unified research system - the most integrated health research system in the world.
Natalie WilsonBusiness Development Manager
Theo ChristieBusiness Development Manager
Sinead CollingeOperations and Business Development Manager
Neem Biotech is an R&D pharmaceutical biotech with expertise in novel antimicrobial research and drug development based on bacterial quorum sensing inhibition pathways.
Neem is a virtual SME with a footprint in South Wales. It has in-house chemistry and biology expertise and a leadership team with extensive antibacterial drug development experience. Neem is also linked in to a network of clinical and disease-area experts in wound and respiratory indications.
Dr Graham DixonCEO Neem Biotech
Heather GrazCommercial Development Manager Neem Biotech
OBN is the UK’s largest and most innovative not-for-profit R&D Membership organisation for Life Sciences with over 400-member companies, ranging from start-ups through unicorns to Big Pharma, and relevant service sector providers. www.obn.org.uk
Our services include discounted purchasing, professional training, advising, advocacy, networking and partnering via c40 high-quality networking events per year throughout the UK. These are complimented by our four, annual, flag-ship events:
BIOTRINITY®, London 30th April – 1st May 2019: Europe’s leading Biopartnering and Investment conference. www.biotrinity.com
BIOSEED®, London, 20th Jan 20120: A unique platform for early-stage Life Sciences Companies seeking seed and series-A funding. www.bioseed.eu
BIOFORWARD®, Birmingham, 11th Oct 2019: A high-quality international partnering conference providing a roadmap for R&D companies looking to achieve sustainable business growth. www.bioforward.co.uk
OBN AWARDS, Oxford, 7th Nov 2019: A leading Life Sciences awards event, celebrating innovation & outstanding achievement across the UK Life Sciences Industry. www.obn-awards.com
Dr John HarrisCEO
Established in 1997, One Nucleus is an award winning not-for-profit Life Sciences & Healthcare membership organisation centred on the Greater London-Cambridge-East of England corridor. Headquartered in Cambridge, at the heart of Europe’s largest Life Sciences & Healthcare cluster, we support those institutions, companies and individuals undertaking activity in or with the above region.
Through providing the local, UK-wide and international connectivity, One Nucleus seeks to enable our members to maximise their performance. This support helping them achieve, or better still exceed, the goals they have set for themselves. Biomedical and Healthcare R&D have always been impactful in driving social and economic progress. In an increasingly outsourced, collaborative and multi-disciplinary sector, bringing the best people together is key to translating great innovation into great products that markedly improve patient outcomes and drive economic development. Attracting and enabling the best people to engage with is at the heart of the One Nucleus team ethos and what we continually strive to deliver.
Dr Tony JonesCEO
OxStem is a drug discovery company, spun-out from the University of Oxford, with the unique vision of developing in-situ cell programming therapies to treat what are typically (but certainly not exclusively) age-related conditions, such as Dementia, Heart Failure, Macular Degeneration (the leading cause of blindness in the developed world), Diabetes and Oncology.
The idea is straightforward – to use the Stem Cell and Medicinal Chemistry expertise within Chemistry and its associated partners at Oxford to identify new classes of drugs that can re-program or stimulate existing endogenous cells – awakening previously defunct or dormant cellular processes.
Dr Carolyn PorterChief Business Officer
Dr Amy VarneyVP Operations
Precision for Medicine, Oncology and Rare Disease
Precision for Medicine, Oncology and Rare Disease is the first comprehensive, fully integrated CRO devoted to oncology and rare disease combining this unique experience with Omics, big data + biomarker-guided drug development.
Precision’s uniquely integrated offering enables the science of precision medicine by combining novel clinical trial designs, industry-leading operational and medical experts, advanced biomarker solutions, and an unequivocal passion for rare diseases and oncology. We provide an uncommon array of talent and services to enable our pharmaceutical and life sciences clients to access new advancements, stay ahead of regulatory changes and ultimately achieve their goals faster. The result: a tailored pathway to approval for oncology and rare disease innovators.
Angelique HeckmannDirector, Strategic Development, Europe
Scottish Development International
Scottish Development International (SDI) is part of Scotland’s main enterprise, innovation and investment agency and works to help international companies find partners in Scotland and Scottish companies develop their business overseas. SDI also works to attract inward investment and knowledge to Scotland in order to help the economy grow.
SDI has a network of offices around the world and provides a wide range of support services covering each phase of international activity, including: business mentoring, market intelligence, business location information and investor aftercare.
The Scottish Life Sciences sector counts more than 700 organisations and 35,000 people with particular strengths in supporting drug discovery and development, regenerative medicine/stem cells, animal health, medical devices, digital health and clinical translational medicine.
Selcia, now part of Eurofins, is a global leader in 14C custom radiolabelling, stable isotope labelling and analytical services. With many years of experience our team of expert synthetic radiochemists can prepare radiolabelled molecules of almost any complexity for use in regulatory studies by the life sciences and chemical industries to understand: preclinical and clinical drug metabolism, human mass balance (GMP 14C Radiolabelled API), dermal penetration, tissue distribution and environmental fate. Selcia also offers GLP NMR and analytical problem solving services to support regulatory submissions, as well as the profiling and synthesis of metabolites and process impurities.
David CarverBusiness Development
Exhibiting at booth 4
SQN Clinical is one of the largest specialist Biometrics CROs in Europe and is the preferred clinical development partner for many pharmaceutical, biotechnology and animal healthcare companies in the UK, Europe and the rest of world. We have a breadth of experience in many therapeutic areas as well as clinical development phases. Noted for our flexibility we support the diverse needs of large and small organisations alike but always provide the assurance that advice and services offered will always meet development and regulatory needs.
For a demo of the system come and see us at booth 4